Recent Advancements in Cardiac Pacing
The basic design of cardiac pacing devices has not significantly changed since the mid-1960s and their limitations are well known.
Recent advancements have attempted to address these limitations by reducing hardware and improving cardiac efficiency. These attempts include the advent of leadless pacemaker systems as well as attempts to improve cardiac efficiency with permanent His bundle pacing (PHBP), algorithms designed to mimic normal physiology and new technologies for cardiac resynchronisation therapy (CRT).
Leadless Pacemakers
Leadless pacemakers represent a fundamental paradigm shift in the design of pacemaker systems with the goal of creating small, completely intracardiac units without transvenous leads and disconnected from any extravascular components. Two designs have been explored for leadless pacemakers -single and multicomponent systems.
A single-component system has an individual, small unit which contains the entire pacemaker (battery, electronics and electrodes) which is implanted in the heart using a deflectable delivery sheath ( Figure 4 ). This simple design allows easy implantation of an energy-efficient system and eliminates the need for extravascular components and leads.
The commercially available leadless pacemakers that are currently used are of this design. However, there are limitations of this system, most notably the difficulty with device retrieval for infection, premature device failure, or battery depletion. There are also uncertain risks such as thrombus formation and risk of infection. In addition, the currently available systems can only be used for single chamber ventricular pacing (VVI or VVIR), limiting their widespread applicability. For most patients with sinus node dysfunction and AV block, a single chamber leadless pacemakers is a suboptimal choice compared with a dual chamber pacemaker; therefore, they are largely limited to patients 
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with permanent AF and slow ventricular response or those with paroxysmal, infrequent AV block. 7 Efforts are currently underway to develop a dual chamber design, though challenges with device-todevice communication and active fixation in the thin-walled right atrium will need to be overcome.
Two leadless pacing devices were available in the US, including the Nanostim ™ leadless cardiac pacemaker (Abbott) and the Micra ™ transcatheter pacing system (Medtronic). However, the Nanostim device was recalled in 2016 due to issues of premature battery depletion and is not currently available. In clinical trials, both systems demonstrated a high rate of successful implantation (>95%). 8, 9 However, there was a 4-6.5% rate of major complications, including perforations or pericardial effusions in 1.5-1.6% of cases. 8, 9 Pacemaker measurements were stable at 6 months. 8, 9 In analyses comparing patients with leadless pacemakers to a cohort of patients with transvenous pacemakers, there were fewer short 
Permanent His Bundle Pacing
Chronic RV apical pacing is non-physiological and has been associated with an increased risk of heart failure, AF and death. This has 
A leadless pacemaker (red circle) is inserted into the right ventricle via a catheter delivery system (red arrows). A large sheath is placed in the right femoral vein and advanced to the inferior vena cava. Through this sheath, the catheter delivery system is advanced into the right atrium and across the tricuspid valve. The delivery system is used to position and deliver the leadless pacemaker in a septal location within the right ventricle.

A: The fluoroscopic image shows an octapolar His catheter (black, dashed arrow) that was placed via the femoral vein as a fluoroscopic marker. The delivery sheath (C315HIS, Medtronic) was been positioned at the atrioventricular septum and the tip of the permanent His bundle pacing lead (3830 SelectSecure ™ , Medtronic) is exposed to obtain unipolar recordings on the pacing system analyser (PSA) or on the electrophysiology lab recording system. Three distinct signals are seen: atrial (A), His bundle electrogram (H) and a ventricular electrogram (V). B: Once a satisfactory location has been found, the lead is manually rotated into the septal myocardium and the sheath is pulled back to expose the ring electrode (red circle). Bipolar recordings on the PSA are shown with an unusually distinct A, H and V signal demonstrated. The octapolar His catheter (black, dashed arrow) has moved from its previous position at the His bundle.
have been developed to describe the various electrocardiographic findings including selective His bundle capture (His bundle capture alone; Figure 6A ) and non-selective His bundle capture (His bundle capture along with RV septal capture; Figure 6B ).
Data have shown that the implant success rate for PHBP ranges from 70-90%. 13, 14 Lead thresholds tend to be higher than traditional RV apical leads; however, the thresholds appear to remain stable over time. PHBP was found to have a statistically significant reduction in a combined endpoint of hospitalisation for heart failure, death or upgrade to biventricular pacing when compared with patients undergoing traditional RV apical pacing (HR 0.71; p<0.02). This effect was most pronounced when the RV pacing burden is more than 20% and was largely driven by a reduction in heart failure events. 13 This technique has also been shown to be effective in instances of complete AV block and in patients with right and left bundle branch block ( Figure 7 ). The ability to reverse left bundle branch block (LBBB) and normalise the QRS has led to an interest in using PHBP for CRT. 17 Additional data will be needed from upcoming trials to compare these two methods . 18 There was no difference in outcomes seen between the PHBP group and traditional CS group in this pilot study; however, there was a high crossover rate between the two groups. A method involving transseptal, direct left bundle stimulation from the RV has achieved QRS normalisation, even in patients where the LBBB cannot be corrected with PHBP. 19 
Closed Loop Stimulation
In an effort to improve upon the traditional rate-drop response algorithm and create a more physiologic response to the need for pacing, closed loop stimulation has been developed by Biotronik. The algorithm measures RV impedance, a surrogate for cardiac contractility, and uses this information to adjust the pacing rate before a sudden drop in heart rate. There has been some success with the treatment of vasovagal syncope with this algorithm although a large, multicentre, 1 1 1 1 16 16 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 13:5 13 
Drugs and Devices
compared with bipolar leads. 21 A natural extension of these benefits is the concept that pacing from more than one LV site may allow for improved resynchronisation and outcomes.
Multisite pacing refers to the concept of using two or more epicardial CS leads to improve the resynchronisation response. Implantation of two or more CS leads has been shown to be feasible and safe. Small studies have shown benefits of this technique in haemodynamic response, ejection fraction, LV end systolic volume and heart failure symptoms. 22 However, the use of a Y-adaptor to pace between the two leads can result in the use of high outputs and early battery depletion. 23 Additional studies are needed for effectiveness of this technique as the results have been mixed. 24 Multipoint pacing refers to pacing from multiple LV sites through a single quadripolar lead. By choosing widely spaced electrodes, a large region of LV myocardium can be captured to provide the best haemodynamic response. This option appears safe and feasible and small studies have shown haemodynamic advantages to multipoint pacing. 25 However, a recently published study has shown no initial benefit with multipoint pacing in patients who are CRT non-responders. 26 Additional phase II data from this study and other ongoing studies will be needed to assess whether there is a significant advantage to this technique.
Endocardial LV pacing
Epicardial CS lead placement, while successful, is hampered by multiple mechanisms of non-response. Fundamentally, it is a nonphysiologic form of pacing as cardiac electrical activation normally proceeds from the endocardium to the epicardium. In addition, CS lead placement relies on the existing coronary venous anatomy, which may be unsuitable for optimal lead placement.
Endocardial LV lead placement has been explored as an alternative to allow for more targeted LV lead placement with a more physiologic ventricular activation and no risk of phrenic nerve capture. This has been accomplished by using conventional pacing leads placed through the interatrial or interventricular septum, as well as a leadless system that involves retrograde aortic implantation of a wireless, endocardial pacing electrode. [27] [28] [29] Despite the attractive features of this technique, even those studies that have shown some indication of clinical benefit have shown a high rate of adverse events, including systemic thromboembolism and procedural complications. 29, 30 Additional improvements in the delivery systems, increased familiarity with anticoagulation requirements for left-sided lead implantation and further studies will hopefully help to reduce complication rates and improve outcomes with this technique.
Future Directions
Future developments for pacemakers will see a continued reduction in hardware. In current pacemaker systems, battery depletion and subsequent generator changes present additional risk of complications, especially infection. Preliminary work has been done to look at using flexible sheets of piezoelectric wires to convert cardiac motion to energy to power pacemaker devices in a nearly inexhaustible manner. 31 There have also been efforts at creating biologic pacemakers using gene therapy to increase automaticity of existing non-pacemaker cardiac myocytes. 32, 33 This research is still in its early stages.
Conclusion
Pacemakers were initially developed in an effort to prevent catastrophic, bradycardic events. These simple devices have evolved into modern systems with significant complexity and a high degree of programmability. However, the overall design of pacemaker systems has not significantly changed in more than 50 years, until recently. 
Clinical Perspective
• Cardiac pacing design had remained largely unchanged for more than 50 years.
• Leadless pacemakers represent a paradigm shift in the design of pacemaker systems, allowing for a significant reduction in hardware and potential reduction in complications.
• Permanent His bundle pacing represents a fundamental shift in the approach to cardiac pacing, focusing on physiological stimulation of the cardiac muscle to improve cardiac efficiency.
• Multisite and multipoint pacing represent efforts in the field of cardiac resynchronisation therapy to improve cardiac efficiency and improve clinical outcomes.
